JingYi Zhao, Min Li, KaiLe Ma, Rui Hao, LiJuan Zhou
{"title":"八段锦对代谢综合征的疗效:系统回顾和荟萃分析综述","authors":"JingYi Zhao, Min Li, KaiLe Ma, Rui Hao, LiJuan Zhou","doi":"10.1002/acm4.3","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This meta-analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk-of-bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], <i>p</i> < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], <i>p</i> < 0.00001). Waist-to-hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], <i>p</i> = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], <i>p</i> = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], <i>p</i> = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], <i>p</i> < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], <i>p</i> = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], <i>p</i> = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], <i>p</i> = 0.003), and low-density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], <i>p</i> = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity-related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.</p>\n </section>\n </div>","PeriodicalId":100029,"journal":{"name":"Advanced Chinese Medicine","volume":"1 1","pages":"66-78"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.3","citationCount":"0","resultStr":"{\"title\":\"The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta-analyses\",\"authors\":\"JingYi Zhao, Min Li, KaiLe Ma, Rui Hao, LiJuan Zhou\",\"doi\":\"10.1002/acm4.3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>This meta-analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk-of-bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], <i>p</i> < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], <i>p</i> < 0.00001). Waist-to-hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], <i>p</i> = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], <i>p</i> = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], <i>p</i> = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], <i>p</i> < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], <i>p</i> = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], <i>p</i> = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], <i>p</i> = 0.003), and low-density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], <i>p</i> = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity-related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.</p>\\n </section>\\n </div>\",\"PeriodicalId\":100029,\"journal\":{\"name\":\"Advanced Chinese Medicine\",\"volume\":\"1 1\",\"pages\":\"66-78\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acm4.3\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced Chinese Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acm4.3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Chinese Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acm4.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
这项荟萃分析评估了八段锦对代谢综合征(MetS)患者代谢状况的影响。截至 2022 年 8 月 19 日,我们对英文(PubMed、Embase、Web of Science 和 Cochrane Library)和中文(CNKI、万方、中国生物医学数据库、VIP)数据库进行了全面检索。纳入的随机对照试验(RCT)均以八段锦治疗 MetS 患者为研究对象。使用 Cochrane 偏倚风险工具对数据进行汇总和评估。采用系统综述的推荐、评估、开发和评价等级来评估文献质量。巴杜安金显著改善了空腹血糖(平均差 [MD] = -0.41,95% 置信区间 [CI] [-0.22, -0.61],p < 0.0001)和糖化血红蛋白水平(MD = -0.99,95% CI [-0.38, -1.60], p < 0.00001)。腰臀比(MD = -0.04,95% CI [-0.03,-0.06],P =0.002)、体重指数(MD =-1.60,95% CI [-0.10,-3.10],P =0.04)、空腹胰岛素(MD = -4.82,95% CI [-0.10,-3.10],P =0.0001)和糖化血红蛋白水平(MD = -0.99,95% CI [-0.38,-1.60],P <0.00001)。82,95% CI [-0.15,-8.59],P = 0.01)、收缩压(MD = -7.16,95% CI [-5.16,-9.17],P <0.00001)、舒张压(MD = -3。43,95% CI [-0.62,-6.24],p = 0.02)、总胆固醇(MD = -0.48,95% CI [-0.10,-0.85],p = 0.01)、甘油三酯(MD = -0.39,95% CI [-0.14,-0.64],p = 0.003)和低密度脂蛋白胆固醇(MD = -0.52,95% CI [-0.10,-0.94],p = 0.01)也显著改善。无不良事件报告。文献质量从很低到中等不等。巴豆神能有效改善 MetS 患者的代谢状况,包括血糖、血脂、肥胖相关指标、胰岛素水平和血压。然而,总体文献质量为中低水平。考虑到干预方法、内容和研究方法,还需要进一步进行严格的 RCT 研究,以探讨八段锦对 MetS 的影响。
The effectiveness of Baduanjin on metabolic syndrome: An overview of systematic reviews and meta-analyses
Objective
This meta-analysis evaluated the effects of Baduanjin on the metabolic status of individuals with metabolic syndrome (MetS). The aim was to identify effective interventions for MetS prevention and treatment.
Methods
We conducted a comprehensive search of English (PubMed, Embase, Web of Science, and Cochrane Library) and Chinese (CNKI, Wanfang, Chinese Biomedical Database, VIP) databases till August 19, 2022. Randomized controlled trials (RCTs) focusing on Baduanjin for MetS patients were included. Data were pooled and assessed using the Cochrane risk-of-bias tool. The Grades of Recommendation, Assessment, Development, and Evaluation for Systematic Reviews was used to evaluate literature quality.
Results
Eight RCTs involving 435 participants were included. Baduanjin showed significant improvements in fasting blood glucose (mean difference [MD] = −0.41, 95% confidence interval [CI] [−0.22, −0.61], p < 0.0001) and glycated hemoglobin levels (MD = −0.99, 95% CI [−0.38, −1.60], p < 0.00001). Waist-to-hip ratio (MD = −0.04, 95% CI [−0.03, −0.06], p = 0.002), body mass index (MD = −1.60, 95% CI [−0.10, −3.10], p = 0.04), fasting insulin (MD = −4.82, 95% CI [−0.15, −8.59], p = 0.01), systolic blood pressure (MD = −7.16, 95% CI [−5.16, −9.17], p < 0.00001), diastolic blood pressure (MD = −3.43, 95% CI [−0.62, −6.24], p = 0.02), total cholesterol (MD = −0.48, 95% CI [−0.10, −0.85], p = 0.01), triglycerides (MD = −0.39, 95% CI [−0.14, −0.64], p = 0.003), and low-density lipoprotein cholesterol (MD = −0.52, 95% CI [−0.10, −0.94], p = 0.01) also significantly improved. No adverse events were reported. Literature quality ranged from very low to moderate.
Conclusions
Baduanjin effectively improves metabolic status in individuals with MetS, including blood glucose, lipid profile, obesity-related indicators, insulin levels, and blood pressure. However, the overall literature quality is moderate to low. Further rigorous RCTs are needed to explore Baduanjin's effects on MetS, considering intervention methods, content, and research methodologies.